Frontlight ResearchEarly access
Taking people in NetherlandsPhase 4
Tests a branched-chain amino acid approach in adults with type 2 diabetes
Tests boosting amino acid breakdown in adults with type 2 diabetes.
Key facts
- Who runs it
- Maastricht University
- Where
- Maastricht, NetherlandsSee the site
- Trial code
- Registry title
- Role of BCAA in glucose homeostasis
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 26 people, planned
- Started
- 14 Apr 2025
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional
- Record updated
- 12 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 76 with type 2 diabetes that is fairly well controlled. Women must be past menopause.
- Age
- Men: 40 to 76 years. Women: 45 to 76 years and post-menopausal (at least 1 year since periods stopped).
- Sex
- Men and women (women must be post-menopausal).
- Disease stage
- Type 2 diabetes diagnosed at least 1.5 years ago, fairly well controlled (HbA1c below 8.5% (69 mmol/mol)). No signs of active diabetes-related problems such as active heart disease, active diabetic foot, nerve damage or eye damage. BMI 25-38 kg/m2.
- Earlier treatment
- Must take only metformin, alone or with sulfonylurea medicines and/or a stable dose of a DPPIV inhibitor for at least the last 3 months.
- Biomarker or test result
- HbA1c below 8.5% (69 mmol/mol).
Main reasons for not taking part
- Type 2 diabetes treated with insulin
- Heart failure, or severe kidney or liver problems
- Weight change of more than 5 kg (11 lb) in the last 3 months
- Being in a study of an investigational product in the last 3 months
- Any reason that makes an MRI scan unsafe, such as a pacemaker or cochlear implant
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patients are able to provide signed and dated written informed consent prior to any study specific procedures
- No signs of active liver or kidney malfunction
- Women are post-menopausal (defined as at least 1 year post cessation of menses) and aged ≥ 45 and ≤ 76 years. Males are aged ≥ 40 years and ≤ 76 years
- Patients should have suitable veins for cannulation or repeated venipuncture
- Caucasians
- BMI: 25-38 kg/m2
- Diagnosed with T2D at least 1.5 years before the start of the study
- Relatively well-controlled T2D: HbA1c < 8.5%
- Oral glucose lowering medication: metformin only or in combination with sulfonylurea agents and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months
- No signs of active diabetes-related co-morbidities like active cardiovascular diseases, active diabetic foot, polyneuropathy or retinopathy
Who cannot take part
- Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator
- Patients using Probalan (probenecid), Haldol (haloperidol), Depakene (valproate) or medical products containing corticosteroids
- Any contra-indication MRI scanning. These contra-indications include patients with e.g. the following: • Central nervous system aneurysm clip • Implanted neural stimulator • Implanted cardiac pacemaker of defibrillator • Cochlear implant • Metal containing corpora aliena in the eye or brains
- Patients with congestive heart failure and and/or severe renal and or liver insufficiency or known sodium retention with oedema
- Men: Hb <8.4 mmol/L, Women: Hb <7.8 mmol/l
- Participate in physical activity more than 3 times a week
- Unstable body weight (weight gain or loss > 5 kg in the last three months)
- Insulin dependent T2D
Where in Netherlands
- Maastricht UniversityMaastricht, NetherlandsTaking people
About the trial
What the trial wants to find out
The primary objective is to investigate if prolonged boosting of BCAA oxidation will substantially lower fasting plasma glucose levels in patients with T2D.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Targeting branched-chain amino acid oxidation to improve glycaemic control in patients with type 2 diabetes
- Plain-language title
- Tests a branched-chain amino acid approach in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 May 2026